By Heather Landi
One of Pennsylvania’s largest health systems is running at 110% capacity, with clinicians practicing “waiting room medicine” on patients who are forced to endure 10- to 20-hour delays in the emergency department.
read more
By Andrea Park,Conor Hale
Even as 2021 looks to be a landmark year for medtech M&A, all signs point to 2022’s tally dwarfing this year's. M&A trends for 2022 will likely shake out into two broad categories: larger players looking for bolt-on deals and mid-size companies wanting to consolidate. And when it comes to who’s buying, the short answer is: everyone.
read more
By Kevin Dunleavy
Novo Nordisk will invest $2.58 billion in expanding production capacity, building three new facilities and adding 400 jobs at its sprawling site in Kalundborg, Denmark. The expansion will help the company meet the growing demand for its diabetes treatments Ozempic and Rybelsus, plus obesity medicine Wegovy.
read more
By Annalee Armstrong
Inquiring minds have wanted to know: what does Pfizer, loaded up with buckets of cash from the successful COVID-19 vaccine Comirnaty, want to buy? Executives gave a preview of what else they want on an investor call to discuss the $6.7 billion acquisition of Arena Pharmaceuticals this morning.
read more
By Robert King
HHS released its unified agenda that details regulations it is planning for next year, including potential regulations for short-term plans and the 340B program.
read more
By Angus Liu
Sanofi and Johnson & Johnson are adding more fuel to their CD38 rivalry fire between Sarclisa and Darzalex in multiple myeloma. With approvals already in place as triplet therapies, the two companies are now touting early clinical wins for four-drug regimens.
read more
By Nick Paul Taylor
The next phase of Novartis’ CAR-T R&D strategy is well underway. With early clinical data on CD19 and BCMA-directed cell therapies in hand, the Big Pharma is preparing to move into registration trials next year.
read more
By Andrea Park
As his second year at the helm of the medtech giant draws to a close, Abbott CEO Robert Ford is adding a new title to his résumé.
read more
By Fraiser Kansteiner
Heading into 2022, large drugmakers are said to have more than $1.7 trillion in their M&A war chests. But after a huge buyout of its own, Bristol Myers Squibb is unveiling another use for its cash—and it's one that pharma often faces criticism for.
read more
By Kyle LaHucik
Eli Lilly has inked a $380 million deal for access to multiple discovery-stage oncology programs from Foghorn Therapeutics. The co-development and co-commercialization agreement gives Lilly access to potential treatments targeting a mutation that is found in about 5% of all tumors.
read more
By Paige Minemyer
Morgan Health, the new healthcare arm of JPMorgan Chase, wants to shift the paradigm for the employer health market to more accountable care. And now, it's making its pitch to providers on why they should be a part of that endeavor.
read more
By Conor Hale
The FDA has begun outlining a potential approach for regulating a cutting-edge front emerging in healthcare: the 3D printing of medical implants or devices customized for each individual patient and manufactured on-site and on-demand within hospitals or doctor’s offices.
read more
